ATE318820T1 - Verfahren zur behandlung von mit p38-kinase assoziierten leiden und pyrrolotriazin- verbindungen als kinaseinhibitoren. - Google Patents

Verfahren zur behandlung von mit p38-kinase assoziierten leiden und pyrrolotriazin- verbindungen als kinaseinhibitoren.

Info

Publication number
ATE318820T1
ATE318820T1 AT01992298T AT01992298T ATE318820T1 AT E318820 T1 ATE318820 T1 AT E318820T1 AT 01992298 T AT01992298 T AT 01992298T AT 01992298 T AT01992298 T AT 01992298T AT E318820 T1 ATE318820 T1 AT E318820T1
Authority
AT
Austria
Prior art keywords
kinase
treating
associated conditions
pyrrolotriazine compounds
kinase inhibitors
Prior art date
Application number
AT01992298T
Other languages
English (en)
Inventor
Katerina Leftheris
Joel Barrish
John Hynes
Stephen T Wrobleski
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE318820T1 publication Critical patent/ATE318820T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
AT01992298T 2000-11-17 2001-11-07 Verfahren zur behandlung von mit p38-kinase assoziierten leiden und pyrrolotriazin- verbindungen als kinaseinhibitoren. ATE318820T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24987700P 2000-11-17 2000-11-17
US31056101P 2001-08-07 2001-08-07

Publications (1)

Publication Number Publication Date
ATE318820T1 true ATE318820T1 (de) 2006-03-15

Family

ID=26940426

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01992298T ATE318820T1 (de) 2000-11-17 2001-11-07 Verfahren zur behandlung von mit p38-kinase assoziierten leiden und pyrrolotriazin- verbindungen als kinaseinhibitoren.

Country Status (31)

Country Link
EP (1) EP1363910B1 (de)
JP (1) JP2004522713A (de)
KR (1) KR100847605B1 (de)
CN (1) CN1622946A (de)
AR (1) AR032637A1 (de)
AT (1) ATE318820T1 (de)
AU (2) AU3276002A (de)
BG (1) BG107750A (de)
BR (1) BR0115446A (de)
CA (1) CA2429628A1 (de)
CY (1) CY1105250T1 (de)
CZ (1) CZ20031370A3 (de)
DE (1) DE60117607T2 (de)
DK (1) DK1363910T3 (de)
EE (1) EE200300227A (de)
ES (1) ES2259051T3 (de)
GE (1) GEP20063915B (de)
HR (1) HRP20030485A2 (de)
HU (1) HUP0303897A2 (de)
IL (1) IL155570A0 (de)
IS (1) IS6816A (de)
MX (1) MXPA03004290A (de)
MY (1) MY127066A (de)
NO (1) NO20032229L (de)
NZ (1) NZ525334A (de)
PE (1) PE20020819A1 (de)
PL (1) PL366376A1 (de)
PT (1) PT1363910E (de)
SK (1) SK5402003A3 (de)
WO (1) WO2002040486A2 (de)
YU (1) YU37903A (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
EP1434991B1 (de) 2001-06-29 2007-10-17 AB Science C-kit inhibitoren
CA2452169A1 (en) 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory diseases
CA2452390A1 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating bone loss
US7700610B2 (en) 2001-06-29 2010-04-20 Ab Science Use of tyrosine kinase inhibitors for treating allergic diseases
PT1401416E (pt) 2001-06-29 2007-02-28 Ab Science Utilização de inibidores de c-kit para tratar doenças inflamatórias intestinais (dii)
GB0124933D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124934D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124936D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
BRPI0307351B8 (pt) 2002-02-12 2021-05-25 Smithkline Beecham Corp composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
ES2334990T3 (es) 2002-02-14 2010-03-18 Pharmacia Corporation Piridinonas sustituidas como moduladores de p38 map quinasa.
US6900208B2 (en) 2002-03-28 2005-05-31 Bristol Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
JP2005529890A (ja) 2002-04-23 2005-10-06 ブリストル−マイヤーズ　スクイブ　カンパニー キナーゼ阻害剤として有用なアリールケトンピロロトリアジン化合物
EP1497019B1 (de) 2002-04-23 2015-05-20 Bristol-Myers Squibb Company Pyrrolo-triazin-anilin-verbindungen als kinaseinhibitoren
US7388009B2 (en) * 2002-04-23 2008-06-17 Bristol-Myers Squibb Company Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
US6933386B2 (en) * 2002-07-19 2005-08-23 Bristol Myers Squibb Company Process for preparing certain pyrrolotriazine compounds
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
WO2004013145A1 (en) * 2002-08-02 2004-02-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
TW200420565A (en) * 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
NZ541232A (en) * 2003-01-09 2008-02-29 Astellas Pharma Inc Pyrrolopyridazine derivatives
MXPA05008183A (es) 2003-02-05 2005-10-05 Bristol Myers Squibb Co Proceso para preparar pirrolotriazina como inhibidores de cinasa.
GB0308186D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308185D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308201D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
AU2004251668B2 (en) 2003-06-03 2008-03-20 Triad Therapeutics, Inc 5-membered heterocycle-based p-38 inhibitors
ES2393950T3 (es) 2003-06-26 2013-01-02 Novartis Ag Inhibidores de la quinasa P38 con base en heterociclos de 5 miembros
DE602004017494D1 (de) 2003-07-25 2008-12-11 Novartis Ag Inhibitoren von p-38-kinase
GB0318814D0 (en) 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds
US7419978B2 (en) * 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
US7102001B2 (en) 2003-12-12 2006-09-05 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine
AU2004309420B2 (en) * 2003-12-23 2008-10-30 Novartis Ag Bicyclic heterocyclic p-38 kinase inhibitors
US7064203B2 (en) 2003-12-29 2006-06-20 Bristol Myers Squibb Company Di-substituted pyrrolotriazine compounds
MY145634A (en) 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
UY28931A1 (es) * 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
US7102002B2 (en) 2004-06-16 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US20050288290A1 (en) * 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7102003B2 (en) 2004-07-01 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine compounds
US7504521B2 (en) 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
TW200618803A (en) 2004-08-12 2006-06-16 Bristol Myers Squibb Co Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
US7151176B2 (en) 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds
ATE480542T1 (de) 2004-10-26 2010-09-15 Novartis Ag Pyrroloä1,2-düä1,2-4ütriazin als inhibitoren von c-jun-n-terminal-kinasen (jnk) und p-38-kinasen
US7405213B2 (en) * 2005-07-01 2008-07-29 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US7402582B2 (en) 2005-07-01 2008-07-22 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
WO2007035428A1 (en) 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Met kinase inhibitors
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
US7514435B2 (en) 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US8063208B2 (en) 2006-02-16 2011-11-22 Bristol-Myers Squibb Company Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
US8268998B2 (en) 2006-11-03 2012-09-18 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
CN101535312B (zh) * 2006-11-03 2013-04-24 百时美施贵宝公司 吡咯并三嗪激酶抑制剂
EP2376491B1 (de) 2008-12-19 2015-03-04 Cephalon, Inc. Pyrrolotriazine als alk- und jak2-inhibitoren
US20120035177A1 (en) * 2009-04-16 2012-02-09 Bristol-Myers Squibb Company Tablet formulation for p38 inhibitor and method
CA2799926A1 (en) * 2010-05-28 2011-12-01 Biocryst Pharmaceuticals, Inc. Heterocyclic compounds as janus kinase inhibitors
CN103012439B (zh) * 2012-11-15 2015-03-11 沈阳药科大学 苯甲酰基取代的噻唑并[3,2-b]-1,2,4-三嗪衍生物及其应用
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
WO2014143607A1 (en) * 2013-03-11 2014-09-18 Bristol-Myers Squibb Company Pyrrolopyridazines as potassium ion channel inhibitors
EP2970294B1 (de) * 2013-03-11 2016-12-28 Bristol-Myers Squibb Company Pyrrolotriazine als kaliumionenkanalhemmer
WO2015054358A1 (en) 2013-10-11 2015-04-16 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2015081783A1 (zh) * 2013-12-06 2015-06-11 江苏奥赛康药业股份有限公司 吡咯并[2,1-f][1,2,4]三嗪类衍生物及其制备方法和用途
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
WO2019071144A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. USE OF P38 INHIBITORS TO REDUCE DUX4 EXPRESSION
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN108516977A (zh) * 2018-07-10 2018-09-11 刘凤娟 一种用于治疗恶性肿瘤的map激酶抑制剂的合成方法
CN112028892B (zh) * 2020-07-29 2022-12-16 天津全和诚科技有限责任公司 4-氨基-吡咯并三嗪衍生物在制备抗肺纤维化制剂中的应用
CN112094219B (zh) * 2020-09-10 2022-08-05 广东莱佛士制药技术有限公司 一种制备钾离子竞争性阻滞剂中间体的方法
EP4504341A1 (de) 2022-04-08 2025-02-12 Shy Therapeutics LLC Verbindungen zur interaktion mit proteinen der ras-superfamilie zur behandlung von krebs, entzündlichen erkrankungen, rasopathien und fibrotischen erkrankungen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2163399A1 (en) * 1994-11-24 1996-05-25 Katsuhiro Kawano Triazine derivative, chymase activity inhibitor and nitric oxide production inhibitor
WO1999024033A1 (en) * 1997-11-12 1999-05-20 Shionogi & Co., Ltd. Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds
CZ303660B6 (cs) * 1999-05-21 2013-02-13 Bristol-Myers Squibb Company Pyrrolotriazin a farmaceutický prostredek s jeho obsahem

Also Published As

Publication number Publication date
MXPA03004290A (es) 2004-02-12
DE60117607D1 (de) 2006-04-27
BR0115446A (pt) 2005-08-09
KR20030045195A (ko) 2003-06-09
JP2004522713A (ja) 2004-07-29
HUP0303897A2 (hu) 2004-03-01
ES2259051T3 (es) 2006-09-16
KR100847605B1 (ko) 2008-07-21
AU2002232760B2 (en) 2006-12-14
EE200300227A (et) 2003-10-15
CY1105250T1 (el) 2010-03-03
CZ20031370A3 (cs) 2003-10-15
WO2002040486A2 (en) 2002-05-23
HK1057555A1 (en) 2004-04-08
HRP20030485A2 (en) 2004-08-31
PT1363910E (pt) 2006-05-31
PL366376A1 (en) 2005-01-24
EP1363910A2 (de) 2003-11-26
NO20032229L (no) 2003-07-16
EP1363910B1 (de) 2006-03-01
CA2429628A1 (en) 2002-05-23
DE60117607T2 (de) 2007-01-25
NO20032229D0 (no) 2003-05-16
PE20020819A1 (es) 2002-09-11
BG107750A (bg) 2004-01-30
YU37903A (sh) 2006-05-25
SK5402003A3 (en) 2004-06-08
WO2002040486A3 (en) 2003-09-12
AU3276002A (en) 2002-05-27
NZ525334A (en) 2005-07-29
DK1363910T3 (da) 2006-06-26
AU2002232760C1 (en) 2002-05-27
CN1622946A (zh) 2005-06-01
MY127066A (en) 2006-11-30
AR032637A1 (es) 2003-11-19
GEP20063915B (en) 2006-09-11
IS6816A (is) 2003-05-14
IL155570A0 (en) 2003-11-23

Similar Documents

Publication Publication Date Title
DE60117607D1 (de) Verfahren zur Behandlung von mit p38-Kinase assoziierten Leiden und Pyrrolotriazin-Verbindungen als Kinaseinhibitoren.
DE60120520D1 (de) Verfahren zur behandlung von abwasser
DE60104188D1 (de) Verfahren und vorrichtung zur behandlung von wasser/abwasser
DE60122532D1 (de) Verfahren zur behandlung von mehreren bohrlochintervallen
DE60045416D1 (de) Verfahren zur behandlung von mikroelektroniksubstraten
ATE259245T1 (de) Verfahren zur behandlung von beweggungsstörungen
DE60227095D1 (de) Zusammensetzungen und verfahren zur behandlung von abgebundenem gips
DE69928237D1 (de) Verfahren zur behandlung von abwasser zur entfernung von organischen stoffen und stickstoff,
EP1469871A4 (de) Verfahren zur behandlung von apoptose und zusammensetzungen dafür
ATE230617T1 (de) Verfahren und methode zur behandlung von abfällen
DE60216514D1 (de) Verfahren zur behandlung von dämpferkondensat
DE60122839D1 (de) Verfahren zur Behandlung von chromatbelastetem Abwasser
ATA17552001A (de) Verfahren zur behandlung säurehältiger abwässer
EP1635801A4 (de) Verfahren zur behandlung und prävention von herzarrhythmie
DE69835419D1 (de) Verfahren zur Behandlung von organischem Abwasser
EP1542702A4 (de) Verfahren und zusammensetzungen zur behandlung von neurologischen störungen
ATE463246T1 (de) Formulierung und verfahren zur behandlung von thrombocythämie
DE50213931D1 (de) Verfahren und vorrichtung zur behandlung von fehlerverdacht
EP1200538A4 (de) Verfahren zur behandlung von petroleumsäuren
DE60129700D1 (de) Verfahren und vorrichtung zur behandlung von abwasser kationischer elektroabscheidungsüberzugs-beschichtungsverfahren
EP1435979A4 (de) Verfahren zur behandlung von multipler sklerose
DE602004010548D1 (de) Verfahren zur behandlung von tierhäuten
DE60101333D1 (de) Verfahren zur behandlung von stickstoff- und/oder phosphor- und/oder organischen stoffen- und/oder schwermetalle enhaltendem abwasser
DE60103939D1 (de) Gehärteter Kautschuk und Verfahren zur Behandlung von gehärtetem Kautschuk
ATA20122001A (de) Verfahren zur behandlung von cellulosischen formkörpern

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1363910

Country of ref document: EP

REN Ceased due to non-payment of the annual fee